Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutidehivcardiovascularglp-1

Semaglutide studied for subclinical cardiovascular health in people with HIV

The journal AIDS reports on effects of the GLP-1 receptor agonist on early cardiovascular markers in an HIV population.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 20:00 ETSource: AIDS (London, England)

The wire

  1. 01A study in AIDS assessed semaglutide's effects on subclinical cardiovascular health among people living with HIV.
  2. 02People with HIV face elevated cardiovascular risk, making metabolic drug effects clinically relevant.
  3. 03Study design, sample size and measured outcomes are not specified in the excerpt.

From the source

Effects of semaglutide on subclinical cardiovascular health in people with HIV

AIDS (London, England) · 2026 Sep 17 · Daher J, Koberssy Z, Moussallem N et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42752515/